Literature DB >> 10928588

Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.

E Růzicka1, J Roth, R Jech, P Busek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10928588     DOI： 10.1002/1531-8257(200007)15:4<734::aid-mds1022>3.0.co;2-e

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

Review 1.  Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases.

Authors:  Thomas J Feuerstein; Miriam Kammerer; Carl Hermann Lücking; Andreas Moser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

Review 2.  Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem.

Authors:  Romy Hoque; Andrew L Chesson
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

Review 3.  X-linked dystonia parkinsonism: clinical phenotype, genetics and therapeutics.

Authors:  Raymond L Rosales
Journal:  J Mov Disord       Date:  2010-10-30

Review 4.  Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.

Authors:  Antonio Daniele; Francesco Panza; Antonio Greco; Giancarlo Logroscino; Davide Seripa
Journal:  Parkinsons Dis       Date:  2016-05-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.